Novartis Investigative Site

Modena, Emilia-Romagna 41124

0 studies enrolling now · 8 studies all time

What they study most

Cancer, Carcinoma, Renal Cell, Chronic Lymphocytic Leukemia (CLL), IgA Nephropathy, Immunoglobulin A Nephropathy, Leukaemia, Lymphocytic, Chronic, Neoplasms, Breast, Neoplasms, Gastrointestinal Tract, Renal Cell Carcinoma (RCC), Thrombocytopaenia

Studies at this site

• A Study of Zigakibart in Adults With IgA Nephropathy — Running, not enrolling
• LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib — Completed
• A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC) — Completed
• Observational Study of Real World Effectiveness Data and Safety in Patients Receiving Pazopanib With Advanced or Metastatic Renal Cell Carcinoma — Completed
• Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy — Stopped early
• A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS) — Stopped early
• Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL) — Completed
• EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer — APPROVED_FOR_MARKETING